Loading
A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Mural Oncology, Inc, active and no longer recruiting.
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) is a phase 1/2 interventional study registered as NCT04592653 by Mural Oncology, Inc, with 78 participants enrolled, started 2020-09-30 and due to reach its primary completion in 2024-07. Interventions recorded: Nemvaleukin alfa and Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/